Roche's multiple sclerosis drug Ocrevus lowered patients' vaccine responses: study

Roche’s multiple sclerosis newcomer Ocrevus was approved by the FDA last March bearing a warning about immunization. Now, researchers have gathered clinical data showing it could weaken the effectiveness of certain vaccines.